

**Biota Holdings Limited**

ACN 006 479 081

10/585 Blackburn Road  
Notting Hill VIC 3168  
Australia**T** +61 3 9915 3700**F** +61 3 9915 3702**E** info@biota.com.au**W** www.biota.com.au

*For Immediate Release*

Melbourne, Australia — 26 October 2012

## **Supreme Court of Victoria approves scheme of arrangement**

Biota Holdings Limited (ASX:BTA) announces that the Supreme Court of Victoria has today made orders approving the scheme of arrangement between Biota and the holders of its ordinary shares (**Scheme**). The scheme will result in the merger of Biota and Nabi Biopharmaceuticals to form Biota Pharmaceuticals, Inc.

It is expected that a copy of the Court's orders will be lodged with the Australian Securities and Investments Commission on 30 October 2012, at which time the Scheme will become effective. If this occurs, Biota shares will be suspended from trading on the ASX at close of trade on that day.

Biota shareholders who hold shares in Biota on 6 November 2012 will be entitled to receive 0.1249630125 of a share in Biota Pharmaceuticals, Inc. for each Biota share held by them at 7pm on that date. Shares in Biota Pharmaceuticals, Inc. will be issued to Biota shareholders on 9 November 2012, and are expected to trade on NASDAQ on 9 November 2012 (US time), 10 November 2012 (Australian time).

It is the responsibility of each Biota shareholder to confirm their holding before trading in Biota Pharmaceuticals, Inc. shares to avoid the risk of selling shares they do not own. As soon as practicable after the 9 November 2012, Biota shareholders will be sent information from Biota Pharmaceuticals, Inc.'s agent, American Stock Transfer & Trust Company, that details the Biota Pharmaceuticals, Inc. shares held by them.

## **About Biota**

Biota is a leading anti-infective drug development company based in Melbourne Australia, with key expertise in respiratory diseases, particularly influenza. Biota developed the first-in-class neuraminidase inhibitor, zanamivir, subsequently marketed by GlaxoSmithKline as Relenza. Biota research breakthroughs include a series of candidate drugs aimed at treatment of respiratory syncytial virus (RSV) disease and Hepatitis C (HCV) virus infections. Biota has a well advanced program for human rhinovirus (HRV) infection with a completed Phase IIb study in asthmatic subjects.

In addition, Biota and Daiichi Sankyo co-own a range of second generation influenza antivirals, of which the lead product Inavir<sup>®</sup>, is marketed in Japan. Biota holds a contract from the US Office of Biomedical Advanced Research and Development Authority (BARDA) for the advanced development of laninamivir in the USA.

Relenza<sup>™</sup> is a registered trademark of the GlaxoSmithKline group of companies.

Inavir<sup>®</sup> is registered to Daiichi Sankyo.

## **Further information**

### **Investor/Analyst Enquiries**

#### **Biota Holdings Limited**

Peter Cook

T: +61 3 9915 3720

Damian Lismore

T: +61 3 9915 3721

### **Shareholder Enquiries**

Biota Shareholder Information Line

T: 1300 306 230 (within Australia)

T: +61 2 8280 7169 (International)

Between 8.30am and 7.30pm

(Melbourne time)

### **Media Enquiries**

Nerida Mossop, Hinton & Associates

T: +61 3 9600 1979 / M: +61 437 361 433

Felicity Williams, Hinton & Associates

T: +61 3 9600 1979 / M: +61 416 770 012

### **US Enquiries**

Hershel Berry, Blueprint Life Science Group

M: +1 415 505 3749